Inhaled Nitric Oxide Delivery Systems Market size is expected to reach USD 3 Billion by the end of 2036, growing at a CAGR of 6% during the forecast period i.e., 2024-2036. In the year 2023, the industry size of inhaled nitric oxide delivery systems was over USD 600 Million. Hospital admission is required in over 50% of patients with asthma. The key factor fuelling the growth of the global market is increased R&D efforts which have led to novel applications for this technology in the healthcare sector. Moreover, the demand for inhaled nitric oxide delivery systemss worldwide is driven by an aging population with reduced lung function.
The market is growing as more and more people are using nitric oxide inhalation, a minimally invasive treatment. In a study conducted in 2020, inhaled nitric oxide has been shown to be effective in treating SARSCoV2 infection. It is also an effective treatment for COVID19 patients, as with conventional medicines. As a result, demand for inhaled nitric oxide delivery systemss increased during the pandemic.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024 – 2036 |
|
CAGR |
~6% |
|
Base Year Market Size (2023) |
~USD 600 million |
|
Forecast Year Market Size (2036) |
~USD 3 billion |
|
Regional Synopsis |
|
Type (Pediatric, Adult)
Based on type, pediatric segment in the inhaled nitric oxide delivery systems market is anticipated to hold 80% of the revenue share by 2036. In the U.S. alone, nearly 25,000 to 30,000 neonatal HRF cases are reported annually and nearly 50% are cured using INO therapy. For 72 to 96 hours, the average cost of this treatment is almost 150 USD per hour, which represents a total of 97,000 to 130,000 USD per patient. Therefore, a favourable reimbursement policy has been established by the government of many countries in order to cover high healthcare costs and thus improve adoption of INO therapy for newborn children. In most adult infectious diseases, inhaled nitric oxide should be administered at high concentrations and due to a lack of clinical evidence this treatment has been less commonly used in adults. Nitric oxide inhalation is used to treat respiratory conditions in babies and newborns. These illnesses may include persistent pulmonary hypertension of the newborn, a severe condition that arises when a newborn's blood pressure in the lungs is abnormally high, and bronchopulmonary dysplasia, a chronic lung abnormality that can manifest in premature newborns. Treating these issues in infants and young children has shown promise when nitric oxide is inhaled. Therefore, the pediatric population has a significant need for inhaled nitric oxide delivery devices.
End User (Ambulatory Center, Hospitals)
Based on end user, the hospital segment in the inhaled nitric oxide delivery systems market is anticipated to hold 60% of the revenue share during the forecast period. This growth can be attributed to ease of delivery, the ability to liquidate when setting up INOs and monitoring systemss, a high number of personnel who monitor device operation as well as an emergency department. In the world, ARF mortality rates are around 30%. Life support and intensive care, like in the Intensive Care Unit of a hospital, is therefore essential for these patients. This segment is being driven by an increase in hospital admissions.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
Application |
|
|
End User |
|
|
Product |
|
North American Market Forecasts
The inhaled nitric oxide delivery systems market in the North America region is expected to record growth of 35% by the end of 2036. In the region, this growth is due to an increasing number of cases of HRF. Moreover, growth opportunities in the market are expected to be supported by increasing adoption of INO therapy, the presence of advanced medical infrastructure and favourable government initiatives. In the US, asthma affects more than 25 million people. In the United States, the inhaled nitric oxide delivery method is used on a regular basis in phase 2 and phase 3 clinical studies for acute respiratory distress syndrome. In 2020, more than 300,000 deaths from respiratory disorders were recorded in Canada. Five noteworthy respiratory disorders, counting asthma, constant obstructive pulmonary infection, lung cancer, tuberculosis, and cystic fibrosis, beset the larger part of Canadians. As these sicknesses ended up more predominant, the require for breathed in nitric oxide conveyance frameworks within the area is developing beside them.
APAC Market Statistics
The inhaled nitric oxide delivery systems market in the Asia Pacific is expected to grow significantly by the end of 2036. In view of the growing pediatric population, an increase in patients with pulmonary failure, and the presence of locally produced nitric oxide disposables & systemss, the market continues to trend. The expansion of the market in this area is driven by efforts undertaken by governments and healthcare organizations to improve access to INO delivery systemss and treatments, with a particular emphasis on remote and unserved regions. As the region's smoking population rises, respiratory illnesses are also growing more prevalent. Nearly a million people in China are aware that they have COPD. This presents a big opportunity for marketers of INO delivery systemss since it has been clinically demonstrated that nitric oxide inhalation improves arterial blood flow's oxygenation and reduces the need for mechanical breathing assistance in patients with severe acute respiratory syndrome.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?